Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m. Eastern Time. Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interes...
Monitoring for a Pullback We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $257 on IWM (up from $245) continue to hold. We continue to see deterioration in market dynamics, and while we expect a period of consolidation/pullback, the afo...
Angi Inc. to Announce Q4 2025 Earnings on February 10th and Host Earnings Conference Call on February 11th DENVER, Jan. 20, 2026 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, February 10, 2026, Angi Inc. (NASDAQ: ANGI) will post its fourth quarter results and publish CEO Jeff Kip's letter to shareholders, which may include certain forward-looking information, at ir.angi.com/quarterly-earnings. On Wednesday, February 11, 2026, at 8:30 a.m. ET, Angi Inc. will host a conference call to answer questions regarding the company’s fourth quarter results. The live audiocast an...
Millennials Are Driving the Future of Home Spending, According to Angi’s State of Home Spending Report New data finds Millennials spend more per household on home projects overall than any other generation, reshaping how Americans maintain, upgrade, and live in their homes. DENVER, Jan. 20, 2026 (GLOBE NEWSWIRE) -- reveals that Millennials have become the primary drivers of today’s home projects economy, generating the highest total home spending per household of any generation. While Millennials are not yet the largest group of homeowners, they outspend all other generations on a per-...
Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025 SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit’s Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She prev...
Merit Medical to Participate at the J.P. Morgan Healthcare Conference SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference, which is being held at The Westin St. Francis Hotel in San Francisco, California, January 12-15, 2026. To learn more, visit Martha G. Aronson, President and Chief Executive Officer, and Raul Parra, Chief Financial Officer, will present a company overview and update on Tuesday, Ja...
A director at Ligand Pharmaceuticals Inc sold 1,804 shares at 188.310USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Trinity Industries, Inc. (Trinity) and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 9 December 2025 in which we reassessed the appropriateness of the rating...
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate$1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE ...
L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne SKYRIZI®, un inhibiteur de l’interleukine 23 (IL-23), a fait l’objet de deux recommandations consécutives de l’Agence des médicaments du Canada (AMC) visant son remboursement pour le traitement des maladies inflammatoires de l’intestin, initialement pour la maladie de Crohn et maintenant pour la colite ulcéreuse. Ces recommandations s’appuient sur l...
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie c...
A director at Merit Medical Systems Inc sold 10,000 shares at 88.038USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.